158 results on '"Pandite, Lini"'
Search Results
2. Data from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
3. Figures S1-S7 from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
4. Supplementary Methods and Figures and Tables from The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
5. Supplement from HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
6. Supplementary Methods, Figures S1-S2, Table S1-S2 from Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib
7. Data from Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib
8. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
9. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
10. The Small-Molecule VEGF Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma
11. 429 Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer
12. 3 Development of an integrated method to quantify receptor occupancy for agonist immunotherapeutics that stimulate target cells to migrate from the peripheral blood
13. 494 Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas
14. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
15. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
16. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
17. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
18. Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report
19. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
20. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
21. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment
22. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
23. Dabrafenib in BRAF V600E–Mutant Advanced Non-Small Cell Lung Cancer: an Open-label, Single arm, Multicenter, Phase 2 Trial
24. Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.
25. Targeting alpha fetoprotein with TCR engineered T cells in HCC.
26. Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.
27. HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
28. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
29. Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma
30. Preclinical safety testing of an affinity-optimised MAGE-A10 T cell receptor for adoptive T cell therapy
31. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients
32. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
33. Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib
34. Optimizing engineered TCR T cell therapy for synovial sarcoma
35. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma
36. The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
37. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
38. Correlation of chromosome (Chr) 14 loss and 5q gain with outcomes of pazopanib treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC).
39. Assessment of a cell-line-derived HIF1α gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib.
40. Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical Cancer
41. Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
42. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
43. Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer
44. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
45. Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
46. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
47. Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors
48. A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
49. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
50. Phase I Trial of Pazopanib in Patients with Advanced Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.